Pfizer (NYSE:PFE) Earning Positive Media Coverage, Analysis Shows – TechNewsObserver

News articles about Pfizer (NYSE:PFE) have been trending positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of 3.00 on their scale. InfoTrie also assigned media headlines about the biopharmaceutical company an news buzz score of 0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Pfizer’s ranking:

PFE has been the subject of a number of analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Bank of America initiated coverage on Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price for the company. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a report on Tuesday, October 1st. Credit Suisse Group reissued a “hold” rating and set a $41.30 price target on shares of Pfizer in a report on Wednesday, November 6th. Finally, ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Nine research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $43.19.

Shares of PFE stock traded up $0.01 on Monday, hitting $38.29. The stock had a trading volume of 359,697 shares, compared to its average volume of 18,818,588. Pfizer has a twelve month low of $33.97 and a twelve month high of $44.94. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55. The firm has a market cap of $211.90 billion, a P/E ratio of 12.76, a PEG ratio of 3.39 and a beta of 0.66. The company has a fifty day moving average price of $37.58 and a two-hundred day moving average price of $38.89.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. During the same period in the prior year, the company earned $0.78 earnings per share. The company’s revenue for the quarter was down 4.6% compared to the same quarter last year. On average, analysts expect that Pfizer will post 2.97 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were issued a $0.36 dividend. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.76%. Pfizer’s dividend payout ratio is presently 48.00%.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.


Leave a Reply